SPRO vs AKTS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SPRO Captures Institutional Edge (3โ1 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Spero Therapeutics, Inc. Common Stock (SPRO) driven by superior Valuation, Growth & Margin, Options & Structure while AKTS counters with relative strength in Momentum & Technical. Fundamentally, SPRO trades at N/M Forward P/E with 14.1% operating margin (-95.6% YoY revenue) versus AKTS at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, SPRO sits in BREAKDOWN (24th %ile IV; Dealer Gamma Walls on Pro) against AKTS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SPRO | AKTS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $58.8M | N/A | Larger Scale | SPRO |
| Trailing P/E Ratio Valuation | 7.2x | N/M | Lower Multiple | SPRO |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -95.6% | N/A | Higher Growth | SPRO |
| Operating Margin (TTM) Profitability | 14.1% | N/A | Higher Margin | SPRO |
| Net Profit Margin Profitability | 15.7% | N/A | Higher Margin | SPRO |
| Return on Equity (ROE) Capital Efficiency | 19.2% | N/A | Higher ROE | SPRO |
| 52-Week Range Position Momentum | 1% ($1โ$3) | 13% ($14โ$34) | Stronger Trend | AKTS |
| Beta / 30D Volatility Risk Regime | 1.75ฮฒ ยท 70% Vol | 1.35ฮฒ ยท 67% Vol | Lower Realized Risk | AKTS |
| Unified Institutional Score Composite Signal | 47.8 / 100 (HOLD) | 30.6 / 100 (SELL) | Higher Composite | SPRO |